Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick J Ward

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Breast Cancer|September 25, 2018
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast CancerDenise A Yardley, Dianna Shipley, John Zubkus, et al.
American Journal of Public Health|September 9, 2021
Disparities in Opioid Overdose Death Trends by Race/Ethnicity, 2018-2019, From the HEALing Communities StudyMarc R Larochelle, Svetla Slavova, Elisabeth D Root, et al.
Cancer Research|February 20, 2004
3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cellsSamuel K Kulp, Ya-Ting Yang, Chin-Chun Hung, et al.
Clinical Breast Cancer|June 22, 2021
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib StudyErika P Hamilton, Virginia Kaklamani, Carla Falkson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2021
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLCChristine L Hann, Timothy F Burns, Afshin Dowlati, et al.
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
JCO Precision Oncology|April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesMakenzi Evangelist, Bo Wang, James E Butrynski, et al.
Breast Cancer Research and Treatment|February 3, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerPatricia A Ganz, Hanna Bandos, Charles E Geyer, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Breast Cancer|September 25, 2018
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Operable HER2-negative Breast CancerDenise A Yardley, Dianna Shipley, John Zubkus, et al.
American Journal of Public Health|September 9, 2021
Disparities in Opioid Overdose Death Trends by Race/Ethnicity, 2018-2019, From the HEALing Communities StudyMarc R Larochelle, Svetla Slavova, Elisabeth D Root, et al.
Cancer Research|February 20, 2004
3-phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cellsSamuel K Kulp, Ya-Ting Yang, Chin-Chun Hung, et al.
Clinical Breast Cancer|June 22, 2021
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib StudyErika P Hamilton, Virginia Kaklamani, Carla Falkson, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 9, 2021
A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLCChristine L Hann, Timothy F Burns, Afshin Dowlati, et al.
The Oncologist|August 18, 2019
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE TrialDavid R Spigel, Dianna L Shipley, David M Waterhouse, et al.
Breast Cancer Research and Treatment|March 1, 2022
Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)Charles E Geyer, Hanna Bandos, Priya Rastogi, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
JCO Precision Oncology|April 22, 2026
Biomarker Testing Rates and Patterns in Patients With Metastatic Non-Small Cell Lung Cancer: A Prospective, Observational Study in Community PracticesMakenzi Evangelist, Bo Wang, James E Butrynski, et al.
Breast Cancer Research and Treatment|February 3, 2022
Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancerPatricia A Ganz, Hanna Bandos, Charles E Geyer, et al.
Pageof 3